Skip to main content
Fig. 5 | BMC Medicine

Fig. 5

From: Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

Fig. 5

Serial monitoring by CSF for osimertinib treatment in patients with LM. A Patient B266: CSF cfDNA sequencing at baseline, disease progression during osimertinib 80 mg treatment, and second progression on osimertinib 80 m combined with bevacizumab. B Patient B176: CSF cfDNA sequencing at baseline, disease progression during osimertinib 80 mg treatment, and second progression on osimertinib 80 m combined with chemotherapy. C Patient B274: CSF cfDNA sequencing at baseline, disease progression during osimertinib 80 mg treatment, and second progression on continuing osimertinib 80 m; D Patient B222: CSF cfDNA sequencing at disease progression during osimertinib 80 mg treatment and second progression on osimertinib 160 mg. Full line indicated mutations annotated by the left vertical axis. Dotted line indicated copy number variations annotated by the right vertical axis. Bev, bevacizumab; chemo, chemotherapy; VAF, variant allelic fraction

Back to article page